The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients: The Transplant Therapeutics Consortium's position statement-Reference-Cited by-同舟云学术

The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients: The Transplant Therapeutics Consortium's position statement

Published:2019-01-23 Issue:3 Volume:19 Page:625-632
ISSN:1600-6135
Container-title:American Journal of Transplantation
language:en
Short-container-title:Am J Transplant

Author:

Stegall Mark D.¹,Troy Somerville Kenneth²,Everly Matthew J.³^ORCID,Mannon Roslyn B.⁴,Gaber A. Osama⁵,First M. Roy⁶⁷,Agashivala Neetu⁸,Perez Vanessa⁹,Newell Kenneth A.¹⁰,Morris Randall E.¹¹,Sudan Debra¹²,Romero Klaus¹³,Eremenco Sonya¹³,Mattera Maria¹³,Spear Nicole¹³,Porter Amy C.¹³,O'Doherty Inish¹³^ORCID

Affiliation:

1. Mayo Clinic Rochester Minnesota

2. Sanofi Genzyme Medical Affairs Cambridge Massachusetts

3. Terasaki Research Institute Los AngelesCalifornia

4. University of Alabama at Birmingham Birmingham Alabama

5. Houston Methodist Houston Texas

6. Transplant Genomics Inc. MansfieldMassachusetts

7. Comprehensive Transplant Center Northwestern University Chicago Illinois

8. Novartis Pharmaceuticals Corporation East Hanover New Jersey

9. Astellas Pharma Global Development, Inc. Northbrook Illinois

10. Emory University School of Medicine AtlantaGeorgia

11. Stanford University School of Medicine Stanford California